Magnetar Capital Partners LP Form 8.3 - Mediclinic International Plc
24 Mai 2023 - 2:44PM
UK Regulatory
TIDMMDC
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Magnetar Capital Partners LP
(b) Owner or controller of interests and short
positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies
is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose Mediclinic International plc
relevant securities this form relates:
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity
of offeror/offeree:
(e) Date position held/dealing undertaken: 23/05/2023
For an opening position disclosure, state
the latest practicable date prior to the
disclosure
(f) In addition to the company in 1(c) above, is NO
the discloser making disclosures in respect of
any other party to the offer?
If it is a cash offer or possible cash
offer, state "N/A"
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one
class of relevant securities of the offeror or offeree named in 1(c), copy
table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant securities of the
offeror or offeree to which the disclosure relates following the dealing (if
any)
Class of relevant security: 10p ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and
/or controlled:
(2) Cash-settled derivatives: 15,233,047 2.06
(3) Stock-settled derivatives
(including options) and
agreements to purchase/sell:
15,233,047 2.06
TOTAL:
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded
options), or agreements to purchase or sell relevant securities, should be
given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and
other employee options)
Class of relevant security in relation
to which subscription right exists:
Details, including nature of the rights
concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of
the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security securities
(b) Cash-settled derivative transactions
Class of Product Nature of Number of Price per
relevant description dealing reference unit
security e.g. CFD e.g. opening/ securities
closing a long/
short position,
increasing/
reducing a long
/short position
Common Swap Increasing a 7,710 GBP5.005000
long position
Common Swap Increasing a 401 GBP5.000012
long position
Common Swap Increasing a 437 GBP5.000023
long position
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry Option
relevant description purchasing, securities price per e.g. date money
security e.g. call selling, to which unit American, paid/
option varying option European received
etc. relates etc. per unit
(ii) Exercise
Class of Product Exercising/ Number of Exercise price per
relevant description exercised securities unit
security e.g. call option against
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit (if
security e.g. subscription, applicable)
conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may be
an inducement to deal or refrain from dealing entered into by the person making
the disclosure and any party to the offer or any person acting in concert with
a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there
are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or
derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant
securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 24/05/2023
Contact name: Julianna Ethell
Telephone number: 847-905-4688
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
END
(END) Dow Jones Newswires
May 24, 2023 08:44 ET (12:44 GMT)
Mediclinic (LSE:MDC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Mediclinic (LSE:MDC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
